Decision: Favourable
Study Title:
ApproaCH: A Phase 2b, Multicenter, Double-Blind, Randomized, Placebo-controlled Trial evaluating Efficacy and Safety of Subcutaneous Doses of TransCon CNP Administered Once Weekly for 52 Weeks in Children with Achondroplasia followed by an Open Label Extension period
NREC Code:
23-NREC-CT-006
Decision:
Favourable
Meeting Date:
25/01/2023
Study Type:
CT application
Principal Investigator:
Dr Ciara McDonnell
PI Institution:
Children's Health Ireland at Temple Street
Sponsor:
Ascendis Pharma Growth Disorders A/S